Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
It’s a day of firsts, with the launch of two new Cambridge, Mass.-based life sciences companies.
Roche and Atea Pharmaceuticals are partnering to develop, manufacture and distribute AT-527, Atea’s experimental antiviral drug against COVID-19.
Finding and developing an effective treatment for nonalcoholic steatohepatitis has, so far, been met with as much futility and frustration as developing a treatment for Alzheimer’s disease. Sagimet Biosciences Chief Executive Officer George Kemble believes his company is on the right path, though.
October is Breast Cancer Awareness month, and Daiichi Sankyo is aiming to raise awareness about one of the most common forms of cancer across the globe.
As we resign ourselves to the fact that the epic SARS-CoV-2 virus that dominated 2020 is going to stubbornly follow us into 2021, we need to learn how to co-exist in temporary tolerance, at least until we have an effective vaccine.
Kite, a Gilead company, is building a franchise, not just a brand, on the promise of its CAR-T cell therapies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
Under terms of the Korsuva deal, Connecticut-based Cara Therapeutics will receive $100 million in an upfront payment, as well as an equity investment of $50 million. Additional milestone payments could bring the total of the deal to about $290 million.
In this multi-target partnership, Genentech will leverage Genesis’ Dynamic PotentialNet AI platform and other novel neural network algorithms.